-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels

Benzinga·10/26/2026 07:12:41
Listen to the news
  • Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels
  • Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy
  • Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol